PeproMene Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.pepromenebio.com
BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-NHL
Phase 1
Recruiting
- Conditions
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- PeproMene Bio, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05370430
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Atrium Health Levine Cancer Institute - Morehead, Charlotte, North Carolina, United States
🇺🇸Providence Swedish Cancer Institute, Seattle, Washington, United States
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
Phase 1
Recruiting
- Conditions
- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- Interventions
- Biological: BAFFR-CAR T cells
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- PeproMene Bio, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04690595
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
© Copyright 2025. All Rights Reserved by MedPath